{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T13:48:15Z","timestamp":1790171295378,"version":"4.1.0"},"reference-count":62,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2022,6,13]],"date-time":"2022-06-13T00:00:00Z","timestamp":1655078400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["R01 DA048029"],"award-info":[{"award-number":["R01 DA048029"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Addiction"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and aims<\/jats:title>\n                    <jats:p>Medication for opioid use disorder (MOUD) reduces harms associated with opioid use disorder (OUD), including risk of overdose. Understanding how variation in MOUD duration influences overdose risk is important as health\u2010care payers increasingly remove barriers to treatment continuation (e.g. prior authorization). This study measured the association between MOUD continuation, relative to discontinuation, and opioid\u2010related overdose among Medicaid beneficiaries.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Retrospective cohort study using landmark survival analysis. We estimated the association between treatment continuation and overdose risk at 5 points after the index, or first, MOUD claim. Censoring events included death and disenrollment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting and participants<\/jats:title>\n                    <jats:p>Medicaid programs in 11\u2009US states: Delaware, Kentucky, Maryland, Maine, Michigan, North Carolina, Ohio, Pennsylvania, Virginia, West Virginia and Wisconsin. A total of 293\u2009180 Medicaid beneficiaries aged 18\u201364\u2009years with a diagnosis of OUD and had a first MOUD claim between 2016 and 2017.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Measurements<\/jats:title>\n                    <jats:p>MOUD formulations included methadone, buprenorphine and naltrexone. We measured medically treated opioid\u2010related overdose within claims within 12\u2009months of the index MOUD claim.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Findings<\/jats:title>\n                    <jats:p>\n                      Results were consistent across states. In pooled results, 5.1% of beneficiaries had an overdose, and 67% discontinued MOUD before an overdose or censoring event within 12\u2009months. Beneficiaries who continued MOUD beyond 60\u2009days had a lower relative overdose hazard ratio (HR) compared with those who discontinued by day 60 [HR\u2009=\u20090.39; 95% confidence interval (CI)\u2009=\u20090.36\u20130.42;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.0001]. MOUD continuation was associated with lower overdose risk at 120\u2009days (HR\u2009=\u20090.34; 95% CI\u2009=\u20090.31\u20130.37;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.0001), 180\u2009days (HR\u2009=\u20090.31; 95% CI\u2009=\u20090.29\u20130.34;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.0001), 240\u2009days (HR\u2009=\u20090.29; 95% CI\u2009=\u20090.26\u20130.31;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.0001) and 300\u2009days (HR\u2009=\u20090.28; 95% CI\u2009=\u20090.24\u20130.32;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.0001). The hazard of overdose was 10% lower with each additional 60\u2009days of MOUD (95% CI\u2009=\u20090.88\u20130.92;\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0&lt;\u20090.0001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Continuation of medication for opioid use disorder (MOUD) in US Medicaid beneficiaries was associated with a substantial reduction in overdose risk up to 12\u2009months after the first claim for MOUD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/add.15959","type":"journal-article","created":{"date-parts":[[2022,6,2]],"date-time":"2022-06-02T09:00:36Z","timestamp":1654160436000},"page":"3079-3088","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":66,"title":["Duration of medication treatment for opioid\u2010use disorder and risk of overdose among Medicaid enrollees in 11 states: a retrospective cohort study"],"prefix":"10.1111","volume":"117","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0625-2861","authenticated-orcid":false,"given":"Marguerite","family":"Burns","sequence":"first","affiliation":[{"name":"Department of Population Health Sciences, School of Medicine and Public Health University of Wisconsin  Madison WI USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Graduate School of Public Health University of Pittsburgh  Pittsburgh PA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chung\u2010Chou H.","family":"Chang","sequence":"additional","affiliation":[{"name":"Department of Medicine, School of Medicine University of Pittsburgh  Pittsburgh PA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joo Yeon","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Health Policy and Management, Graduate School of Public Health University of Pittsburgh  Pittsburgh PA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Ahrens","sequence":"additional","affiliation":[{"name":"Public Health Program, Muskie School of Public Service University of Southern Maine  Portland ME USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsay","family":"Allen","sequence":"additional","affiliation":[{"name":"Health Policy, Management and Leadership Department, School of Public Health West Virginia University  Morgantown WV USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Cunningham","sequence":"additional","affiliation":[{"name":"Health Behavior and Policy Department, School of Medicine Virginia Commonwealth University  Richmond VA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam J.","family":"Gordon","sequence":"additional","affiliation":[{"name":"Department of Medicine and Department of Psychiatry, School of Medicine University of Utah  Salt Lake City UT USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6907-5447","authenticated-orcid":false,"given":"Marian P.","family":"Jarlenski","sequence":"additional","affiliation":[{"name":"Department of Health Policy and Management, Graduate School of Public Health University of Pittsburgh  Pittsburgh PA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Lanier","sequence":"additional","affiliation":[{"name":"Department of Health Policy and Management, Graduate School of Public Health University of Pittsburgh  Pittsburgh PA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Mauk","sequence":"additional","affiliation":[{"name":"School of Social Work University of North Carolina at Chapel Hill  Chapel Hill NC USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Joan","family":"McDuffie","sequence":"additional","affiliation":[{"name":"Government Resource Center, Ohio Colleges of Medicine The Ohio State University  Columbus OH USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shamis","family":"Mohamoud","sequence":"additional","affiliation":[{"name":"Center for Community Research and Service, Biden School of Public Policy and Administration University of Delaware  Newark DE USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffery","family":"Talbert","sequence":"additional","affiliation":[{"name":"Hilltop Institute University of Maryland Baltimore County  Baltimore MD USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kara","family":"Zivin","sequence":"additional","affiliation":[{"name":"Division of Biomedical Informatics, College of Medicine University of Kentucky  Lexington KY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2418-6017","authenticated-orcid":false,"given":"Julie","family":"Donohue","sequence":"additional","affiliation":[{"name":"Department of Health Policy and Management, Graduate School of Public Health University of Pittsburgh  Pittsburgh PA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,6,13]]},"reference":[{"key":"e_1_2_8_2_1","volume-title":"Provisional Drug Overdose Death Counts","author":"Ahmad FB","year":"2021"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1992.03480200058024"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1996.01830050035005"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.281.11.1000"},{"key":"e_1_2_8_6_1","first-page":"8","article-title":"Methadone treatment of opiate addiction: a systematic review of comparative studies","volume":"14","author":"Ali S","year":"2017","journal-title":"Innov Clin Neurosci"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60358-9"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2014.2556"},{"key":"e_1_2_8_9_1","first-page":"530","article-title":"Effectiveness of injectable extended\u2010release naltrexone vs daily buprenorphine\u2013naloxone for opioid dependence: a randomized clinical noninferiority trial","volume":"75","author":"Tanum L","year":"2018","journal-title":"JAMA Psychiatry"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/add.14180"},{"key":"e_1_2_8_11_1","article-title":"Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence","volume":"2","author":"Mattick RP","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1402780"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMsr1706626"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ps.201300256"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2007.11.003"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2013.10.014"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1100\/tsw.2005.52"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13722-021-00223-z"},{"key":"e_1_2_8_19_1","unstructured":"American Society of Addiction Medicine (ASAM).The ASAM National Practice Guideline for the Treatment of Opioid Use Disorder\u20142020 Focused Update.2020. Available at:https:\/\/www.asam.org\/docs\/default-source\/quality-science\/npg-jam-supplement.pdf?sfvrsn=a00a52c2_2(accessed 6 November 2020)."},{"key":"e_1_2_8_20_1","unstructured":"US Department of Veterans Affairs.VA\/DoD Clinical Practice Guideline for the Management of Substance Use Disorders.2015; version 3.0. Available at:https:\/\/www.healthquality.va.gov\/guidelines\/MH\/sud\/VADoDSUDCPGRevised22216.pdf(accessed 6 November 2020)."},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.170958"},{"key":"e_1_2_8_22_1","unstructured":"National Quality Forum.Behavioral Health 2016\u20132017. Final Report.2017. Available at:https:\/\/www.qualityforum.org\/Publications\/2017\/08\/Behavioral_Health_2016-2017_Final_Report.aspx(accessed 30 October 2020)."},{"key":"e_1_2_8_23_1","unstructured":"Substance Abuse and Mental Health Services Administration.TIP 63: Medications for Opioid Use Disorder\u2010 Full Document.2020. Document number PEP20\u201302\u201301\u2010006. Available at:https:\/\/store.samhsa.gov\/product\/TIP-63-Medications-for-Opioid-Use-Disorder-Full-Document\/PEP20-02-01-006?referer=from_search_result(accessed 6 November 2020)."},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2014.5302"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2013.2216"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.2008.02455.x"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.j1550"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2019.02.031"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2006.11.009"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/add.13270"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1377\/hlthaff.2019.01085"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2019.19060612"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/add.14991"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.20622"},{"key":"e_1_2_8_35_1","unstructured":"Kaiser Family Foundation.Medicaid's Role in Addressing the Opioid Epidemic.2018. Available at:https:\/\/www.kff.org\/infographic\/medicaids-role-in-addressing-opioid-epidemic(accessed 14 May 2018)."},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.7326\/M17-3107"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCOUTCOMES.110.957951"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.7374"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2011.236"},{"key":"e_1_2_8_40_1","unstructured":"Substance Abuse and Mental Health Services Administration. Clinical Guideline for Treating Pregnant Women with Opioid Use Disorder and their Infants. Rockville MD:2018. SMA 18\u20135054. Available at:https:\/\/store.samhsa.gov\/product\/Clinical-Guidance-for-Treating-Pregnant-and-Parenting-Women-With-Opioid-Use-Disorder-and-Their-Infants\/SMA18-5054(accessed 19 August 2021)."},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.4772"},{"key":"e_1_2_8_42_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.4157"},{"key":"e_1_2_8_43_1","doi-asserted-by":"publisher","DOI":"10.1097\/MLR.0000000000000727"},{"key":"e_1_2_8_44_1","unstructured":"Assistant Secretary for Planning and Evaluation. Use of Medication\u2010Assisted Treatment for Opioid Use Disorders in Employer\u2010Sponsored Health Insurance: Final Report. Washington DC: U.S. Department of Health and Human Services;2019. Available at:https:\/\/aspe.hhs.gov\/sites\/default\/files\/migrated_legacy_files\/\/186856\/MATOUD.pdf(accessed 20 April 2022)."},{"key":"e_1_2_8_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2017.07.001"},{"key":"e_1_2_8_46_1","doi-asserted-by":"publisher","DOI":"10.1097\/j.pain.0000000000000730"},{"key":"e_1_2_8_47_1","doi-asserted-by":"publisher","DOI":"10.1177\/1060028017751913"},{"key":"e_1_2_8_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2012.11.004"},{"key":"e_1_2_8_49_1","doi-asserted-by":"publisher","DOI":"10.1111\/add.13762"},{"key":"e_1_2_8_50_1","unstructured":"US Department of Agriculture.2010 Rural\u2013Urban Commuting Area (RUCA) Codes. Available at:https:\/\/www.ers.usda.gov\/data-products\/rural-urban-commuting-area-codes\/documentation\/(accesssed 3 September 2021)."},{"key":"e_1_2_8_51_1","doi-asserted-by":"publisher","DOI":"10.1097\/MLR.0000000000000147"},{"key":"e_1_2_8_52_1","doi-asserted-by":"publisher","DOI":"10.1097\/MLR.0b013e31829b1bb1"},{"key":"e_1_2_8_53_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-14-25"},{"key":"e_1_2_8_54_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.1482"},{"key":"e_1_2_8_55_1","doi-asserted-by":"publisher","DOI":"10.1002\/jrsm.1230"},{"key":"e_1_2_8_56_1","doi-asserted-by":"publisher","DOI":"10.1097\/EDE.0000000000000457"},{"key":"e_1_2_8_57_1","unstructured":"US Census Bureau. United States Population Estimates: Nation States Counties and Puerto Rico\u2014April 1 2010 to July 1 2019. Washington DC;2020. Available at:https:\/\/www.census.gov\/data\/tables\/time-series\/demo\/popest\/2010s-state-detail.html(accessed 29 July 2021)."},{"key":"e_1_2_8_58_1","unstructured":"GiffordK EllisE EdwardsBC LashbrookA HintonE AntonisseLet al.Medicaid Moving Ahead in Uncertain Times: Results from a 50\u2010State Medicaid Budget Survey for State Fiscal Years 2017 and 2018. Washington DC: Kaiser Family Foundation;2018. Available at: https:\/\/files.kff.org\/attachment\/Report\u2010Results\u2010from\u2010a\u201050\u2010State\u2010Medicaid\u2010Budget\u2010Survey\u2010for\u2010State\u2010Fiscal\u2010Years\u20102017\u2010and\u20102018(accessed 29 July 2021)."},{"key":"e_1_2_8_59_1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm675152e1"},{"key":"e_1_2_8_60_1","unstructured":"Medicaid and CHIP Payment and Access Commission. Ch 4. Access to Substance use Disorder Treatment in Medicaid in June 2018 Report to Congress. Washington DC;2018. Available at:https:\/\/www.macpac.gov\/wp-content\/uploads\/2018\/06\/Access-to-Substance-Use-Disorder-Treatment-in-Medicaid.pdf(accessed 29 July 2021)."},{"key":"e_1_2_8_61_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2020.108248"},{"key":"e_1_2_8_62_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-021-06969-1"},{"key":"e_1_2_8_63_1","doi-asserted-by":"publisher","DOI":"10.2105\/AJPH.2018.304856"}],"container-title":["Addiction"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/add.15959","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/add.15959","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/add.15959","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T02:20:34Z","timestamp":1692670834000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/add.15959"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,13]]},"references-count":62,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["10.1111\/add.15959"],"URL":"https:\/\/doi.org\/10.1111\/add.15959","archive":["Portico"],"relation":{},"ISSN":["0965-2140","1360-0443"],"issn-type":[{"value":"0965-2140","type":"print"},{"value":"1360-0443","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,13]]},"assertion":[{"value":"2022-01-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-05-13","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-06-13","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}